Accueil   Diary - News   All news Novasep Invests in a €27m Viral Vector Production Facility

Novasep Invests in a €27m Viral Vector Production Facility

The strategic investment supports the growing demand for development and commercial phase production of viral-vector based therapies

 

LYON, France, February 13, 2017b -- The new site, scheduled to be operational in early 2019, will be built at Novasep's facility in Seneffe, Belgium, to complement the existing lab-scale suites of the neighboring site in Gosselies.

 

 

The site will feature two cGMP suites on 2000 sqm. equipped with a set of single-use bioreactors ranging from 200L up to 2000L. It will fit perfectly with the production requirements for phase III and commercial stages.

 

 

Read the press release